Aclaris Therapeutics Inc. (ACRS)
$6.14
$0.19
(3.19%)
As on 04-Sep-2026 13:39EDT
Market cap
$885 Mln
Revenue (TTM)
$8 Mln
P/E Ratio
--
P/B Ratio
7.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
147,198,893
10 Years Aggregate
CFO
$-551.19 Mln
EBITDA
$-661.85 Mln
Net Profit
$-763.85 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| 104.0 | 11.0 | 38.9 | 198.1 | -8.1 | -18.7 | -11.5 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| 21.4 | 134.5 | -93.3 | 8.3 | 124.7 | 242.3 | -74.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
|
6.1 | 884.7 | 8.2 | -75.7 | -921.5 | -66.5 | -- | 7.3 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Aclaris Therapeutics (ACRS)
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug... (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Read more
-
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
-
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
-
Headquarters
Wayne, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aclaris Therapeutics (ACRS)
What is the current share price of Aclaris Therapeutics Inc (ACRS) Today?
The share price of Aclaris Therapeutics Inc (ACRS) is $6.14 (NASDAQ) as of 04-Sep-2026 13:39 EDT. Aclaris Therapeutics Inc (ACRS) has given a return of -8.06% in the last 3 years.
What is the current PB & PE ratio of Aclaris Therapeutics Inc (ACRS)?
Since, TTM earnings of Aclaris Therapeutics Inc (ACRS) is negative, P/E ratio is not available.
The P/B ratio of Aclaris Therapeutics Inc (ACRS) is 7.27 times as on 28-Aug-2026, a 40 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.69 |
3.58 |
2024 |
-1.79 |
1.52 |
2023 |
-0.84 |
0.47 |
2022 |
-12.09 |
5.31 |
2021 |
-9.80 |
4.51 |
What is the 52 Week High and Low of Aclaris Therapeutics Inc (ACRS)?
The 52-week high and low of Aclaris Therapeutics Inc (ACRS) are Rs 6.60 and Rs 1.74 as of 05-Sep-2026.
What is the market cap of Aclaris Therapeutics Inc (ACRS)?
Aclaris Therapeutics Inc (ACRS) has a market capitalisation of $ 885 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aclaris Therapeutics Inc (ACRS)?
Before investing in Aclaris Therapeutics Inc (ACRS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.